How much revenue does Parmax Pharma make?

Parmax Pharma reported 282.04 million INR in revenue for fiscal year 2025, up 155.2% from 110.53 million INR in fiscal year 2024. In Q3 2026 revenue was 43.26 million INR.

What companies are similar to Parmax Pharma?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Concord Drugs Limited (CONCORD.BO), Mercury Laboratories Limited (MERCURYLAB.BO), Shelter Pharma Limited (SHELTER.BO), Kabra Drugs Limited (KABRADG.BO).

Parmax Pharma Limited (PARMAX.BO) Stock

About Parmax Pharma Limited

Parmax Pharma Limited operates in the pharmaceutical business in India. It manufactures and sells bulk drugs, drug intermediates, and specialty chemicals. The company was incorporated in 1994 and is based in Rajkot, India.

At a glance

Parmax Pharma reported revenue of 282.04 million INR for fiscal year 2025, up 155.2% from fiscal year 2024, and net income of -20.94 million INR. In Q3 2026 (the quarter ended December 31, 2025) revenue was 43.26 million INR, down 31.2% from a year before.

Figures from company filings; latest fiscal year ended March 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.